MERIT MEDICAL SYSTEMS INC

Overview

Merit Medical Systems, Inc. is a medical-device company that develops, manufactures, and markets products used in interventional, diagnostic, and therapeutic procedures. Its business is organized around cardiovascular and endoscopy segments, with products used in areas including cardiology, radiology, oncology, critical care, and endoscopy.[1][2]

The company serves markets worldwide. For the year ended December 31, 2025, it reported revenue of $1.516 billion, and its website describes a workforce of approximately 7,000 employees worldwide.[3][4] Merit’s stated mission is “Understand, Innovate, Deliver.” Founded in 1987, the company began with a specialized control syringe used to inject contrast solution for angiograms.[5][6] [1]+5

Products & services

Merit Medical’s products include devices and systems for cardiac and peripheral intervention, oncology, spine procedures and endoscopy, along with procedural kits and OEM components. Its current portfolio is organized into foundational and therapeutic platforms, including access devices, procedural solutions, cardiac therapies, oncology, renal therapies, vascular intervention and endoscopy.[7]

In cardiac access and intervention, products include Prelude introducer sheaths—Prelude Wave with SnapFix technology and Prelude IDeal, an ultra-thin-wall sheath designed to leave more room for catheters and other devices in the radial artery—along with InQwire guide wires, Performa Diagnostic and Ultimate catheters, PreludeSYNC radial compression devices and the SafeGuard femoral hemostasis device. Cardiac rhythm and electrophysiology products include the Evolution lead-removal system, the Worley Advanced LV Delivery System for left-ventricular pacing-lead implantation, and HeartSpan transseptal needles and sheath introducers.[8]+6

Peripheral and oncology products include Q50 and Q50X stent-graft balloon catheters for endovascular aortic repair; Fountain and Mistique infusion systems and catheters for arterial or hemodialysis-graft occlusions and deep-vein thrombosis; and EN Snare and One Snare devices for manipulating, capturing and retrieving foreign material. SCOUT is a nonradioactive, wire-free tumor-localization system, while CorVocet is a soft-tissue core needle biopsy system designed to obtain a full core specimen. Spine products include the StabiliT MX vertebral-augmentation system, Arcadia balloons for creating a controlled cavity, and STAR targeted radiofrequency ablation for palliative treatment of painful metastatic spinal tumors. Endoscopy products include the Resilience through-the-scope esophageal stent, C2 CryoBalloon and EsophyX Z+ GERD treatment system.[15]+10

Merit’s OEM and service offerings include molded components, subassemblies, custom kits and bulk non-sterile goods for medical-device manufacturers; medical-tube and wire coating; and piezoresistive pressure-sensor components supplied as bare die, ceramic-mounted or calibrated products. In FY2025, net sales were $579.840 million in Peripheral Intervention (38.3% of consolidated sales), $448.914 million in Cardiac Intervention (29.6%), $209.333 million in Custom Procedural Solutions (13.8%), $204.955 million in OEM (13.5%) and $72.864 million in Endoscopy Devices (4.8%). Custom Procedural Solutions includes standard and custom procedure kits and packs, safety and waste-management products, and hemostasis accessories.[26]+3 [7]+22

Geographic presence

Merit Medical Systems is headquartered in South Jordan, Utah. Its principal European operations office is in Galway, Ireland; it has a European distribution and customer-service facility in Maastricht, Netherlands, and a principal Asian distribution office in Beijing, China. The company reports manufacturing or packaging operations in the United States, Mexico, the Netherlands, Ireland, France, Brazil, and Singapore, with research and development locations in Utah, California, Texas, Ireland, and France. Its distribution network also includes facilities in Canada, the United Kingdom, South Africa, South Korea, India, New Zealand, Japan, China, Hong Kong, Thailand, Colombia, and Australia, among other locations.[30]+2

Merit sells internationally through company representatives, independent distributors, and custom procedure-tray manufacturers across Europe, the Middle East, Africa, Asia, Oceania, Central and South America, Mexico, and Canada. China is its largest market outside the United States. In 2025, U.S. sales were $909.466 million and international sales were $606.440 million, approximately 60% and 40% of total net sales, respectively; the filing reports the international share as 40%.[33][28] [30]+6

Business segments

Beginning in the first quarter of 2026, Merit Medical Systems reports one operating segment, rather than separate cardiovascular and endoscopy segments. Within that segment, it identifies two product categories: foundational and therapeutic.[34][35]

Foundational products support access and enabling functions in vascular and other procedures. Their platforms include access devices, procedural solutions, OEM, and vascular intervention. Therapeutic products address a broad range of diseases, with platforms including cardiac therapies, oncology, renal therapies, vascular intervention, OEM, and endoscopy.[34][35]

For the six months ended June 30, 2026, foundational products contributed approximately 67% of revenue ($536.440 million of $800.720 million), and therapeutic products approximately 33% ($264.280 million). These are product-category shares within the single reported segment, not separate segment contributions.[36]

In 2025, before the reporting change, the company reported cardiovascular and endoscopy segments. Cardiovascular contributed approximately 95.2% of 2025 revenue ($1,443.042 million), and endoscopy approximately 4.8% ($72.864 million).[37][38] [34]+4

Company history

Merit Medical Systems was founded in Murray, Utah, in 1987 by Fred Lampropoulos, and introduced its first syringe the following year. The company expanded internationally with a manufacturing facility in Galway, Ireland, and established Merit Sensor in 1994; it launched its RADstat compression device in 2000.[6]

Merit broadened its medical-device portfolio through acquisitions, including BioSphere Medical in 2010 and product and business acquisitions involving Argon Medical Devices, Catheter Connections, Brightwater Medical, Cianna Medical, and Vascular Insights from 2017 to 2019.[39]+4 It continued expanding into new procedural areas with the HeRO Graft and Thomas Medical Products acquisitions in 2022, followed by dialysis-catheter, biopsy-sealant, and vascular-access products in 2023.[44]+2

Merit completed its acquisition of Cook Medical’s lead-management portfolio in 2024 and acquired Biolife in May 2025.[47][48] Founder Fred Lampropoulos was succeeded as President and CEO by Martha Aronson effective October 3, 2025.[49][50] In April 2026, Merit completed its acquisition of View Point Medical, adding its OneMark tumor-localization system and tissue markers.[51] [48]+13

Sources

• MERIT MEDICAL SYSTEMS INC — Full financial report (2025 Y)
  32 citations

  [1][2][5][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][37][38][48]
• www.merit.com[3]
• www.merit.com[4]
• www.merit.com[6]
• MERIT MEDICAL SYSTEMS INC — Full financial report (2026 Q 2)
  5 citations

  [7][34][35][36][51]
• www.merit.com[39]
• www.merit.com[40]
• www.merit.com[41]
• www.merit.com[42]
• www.merit.com[43]
• www.merit.com[44]
• www.merit.com[45]
• www.merit.com[46]
• www.merit.com[47]
• www.sec.gov[49]
• www.sec.gov[50]